Clinical Trial Update: Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension [Phase 2, Phase 3]

View source ↗

Summary

The HEADWAY-DLB extension trial of intepirdine (RVT-101) in dementia with Lewy bodies has been terminated. It was a long-term extension of a phase 2/3 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies

Drugs mentioned

• Intepirdine (RVT-101) (Intepirdine)

Snippet

Sponsor: Axovant Sciences Ltd. | Conditions: Dementia With Lewy Bodies | Phase 2, Phase 3 | Status: TERMINATED